Current:Home > MyWegovy patients saw 20% reduction in cardiovascular risks, drugmaker says-LoTradeCoin
Wegovy patients saw 20% reduction in cardiovascular risks, drugmaker says
View Date:2024-12-23 21:32:15
Wegovy, one of a new class of drugs used for weight loss, reduced the risk of heart attacks in overweight adults in a large trial, according to its manufacturer.
Drugmaker Novo Nordisk on Tuesday reported the results of a new study that tracked more than 17,000 adults over the age of 45 who were overweight or obese and had cardiovascular disease but no history of diabetes.
The trial showed that once-weekly Wegovy injections cut the likelihood of serious cardiac events such as heart attacks, strokes and cardiovascular deaths among the study's participants by 20%. That represents a better result than analysts had expected, and the findings could make a strong case for insurers to cover the costly weight-loss drug, Reuters reported.
"The results could improve the willingness to pay for obesity drugs and provide higher incentive to treat obesity at earlier state," noted Henrik Hallengreen Laustsen, an analyst at Jyske Bank, speaking to Reuters.
The trial demonstrates that the medication "has the potential to change how obesity is regarded and treated," Martin Holst Lange, executive vice president for Development at Novo Nordisk, said in a statement.
Wegovy clinical trials
Wegovy, a brand-name formulation of the GLP-1 receptor agonist semaglutide, received approval to treat adult obesity in 2021. An early study showed that patients taking semaglutide lost 15% of their body weight in 68 weeks.
This latest study shows semaglutide can reduce patients' risks of experiencing cardiac events, which are more common in overweight and obese individuals. Obese adults are 28% more likely to develop heart disease compared with adults with a healthy body-mass index, even when they lack other risk factors, a 2018 study showed.
How much is Wegovy?
Even so, some insurers aren't rushing to cover semaglutide.
Wegovy can cost $1,350 per month, according to telehealth and prescription coupon website GoodRx. That's hundreds of dollars more than more traditional weight-loss medications like Orlistat.
Some insurers are paying tens of millions of dollars per month for semaglutide as more Americans are prescribed the medications, the Wall Street Journal reported.
- Ozempic, Mounjaro manufacturers sued over claims of "stomach paralysis" side effects
- Ozempic side effects could lead to hospitalization
- Woman sues drug makers of Ozempic and Mounjaro
That's led some employers, like the University of Texas System, to end coverage of Wegovy for individuals covered by their health plans, according to the Journal. Other employers are implementing coverage restrictions to deal with the medications' rising costs.
Semaglutide safety concerns
Public concerns about the safety of the drug may also be an obstacle to its wider adoption as a first-line treatment against obesity. Patients who have taken Wegovy and other semaglutide-based medications have experienced unpleasant, and sometimes dangerous, side effects, like chronic abdominal pain and hypoglycemia.
Earlier this month, a personal injury law firm filed a lawsuit against the manufacturers of Ozempic, Wegovy and Mounjaro, alleging the drugmakers failed to warn patients the treatments could cause gastroparesis, a painful condition in which food is slow to move through the stomach.
- In:
- Weight Loss
veryGood! (44)
Related
- Wildfires burn from coast-to-coast; red flag warnings issued for Northeast
- Savencia Cheese recalls Brie cheeses sold at Aldi, Market Basket after listeria concerns
- Republican incumbent Josh Hawley faces Democrat Lucas Kunce for US Senate seat in Missouri
- McBride and Whalen’s US House race sets the stage for a potentially historic outcome
- 'Dangerous and unsanitary' conditions at Georgia jail violate Constitution, feds say
- Democratic Rep. Angie Craig seeks a 4th term in Minnesota’s tightest congressional race
- Jonathan Mingo trade grades: Did Cowboys get fleeced by Panthers in WR deal?
- Savencia Cheese recalls Brie cheeses sold at Aldi, Market Basket after listeria concerns
- After Baltimore mass shooting, neighborhood goes full year with no homicides
- Democrat Sheldon Whitehouse seeks a fourth term in the US Senate from Rhode Island
Ranking
- Patrick Mahomes Breaks Silence on Frustrating Robbery Amid Ongoing Investigation
- MLB free agent rankings: Soto, Snell lead top 120 players for 2024-2025
- Fantasy football waiver wire: 10 players to add for NFL Week 10
- Prince's Sister Tyka Nelson Dead at 64
- Question of a lifetime: Families prepare to confront 9/11 masterminds
- McBride and Whalen’s US House race sets the stage for a potentially historic outcome
- GOP senator from North Dakota faces Democratic challenger making her 2nd US Senate bid
- Strike at Boeing was part of a new era of labor activism long in decline at US work places
Recommendation
-
Women suing over Idaho’s abortion ban describe dangerous pregnancies, becoming ‘medical refugees’
-
Queen Camilla Withdraws From Public Engagements Due to Chest Infection
-
Alaska voters deciding a hard-fought race for the state’s only U.S. House seat, election issues
-
South Dakota is deciding whether to protect abortion rights and legalize recreational marijuana
-
'Treacherous conditions' in NYC: Firefighters battling record number of brush fires
-
Gianforte and Zinke seek to continue Republican dominance in Montana elections
-
4 Democratic US House members face challengers in Massachusetts
-
The GOP expects to keep Kansas’ open House seat. Democratic Rep. Davids looks tough to beat